Chlorhexidine Gluconate Rinse
FDA Label NDC 0116-1999

17 label sections · Submitted to the FDA by Xttrium Laboratories, Inc. · Indications, Dosage, Usage, and Precautions

Structured Product Label

The following Structured Product Label (SPL) was submitted to the FDA by Xttrium Laboratories, Inc. for the product Chlorhexidine Gluconate (NDC 0116-1999). This document serves as the official prescribing information, containing essential scientific data and clinical materials required for healthcare providers and patients.

This specific version of the label includes detailed information regarding chlorhexidine gluconate 0.12%, oral rinse, usp, clinical pharmacology, indication, contraindications, warnings, precautions, general precautions, nursing mothers, and other regulatory disclosures. Use the navigation below to review specific sections of the FDA submission.

Contraindications

Chlorhexidine gluconate oral rinse should not be used by persons who are known to be hypersensitive to chlorhexidine gluconate or other formula ingredients.

Warnings

The effect of chlorhexidine gluconate oral rinse on periodontitis has not been determined. An increase in supragingival calculus was noted in clinical testing in chlorhexidine gluconate oral rinse users compared with control users. It is not known if chlorhexidine gluconate oral rinse use results in an increase in subgingival calculus. Calculus deposits should be removed by a dental prophylaxis at intervals not greater than six months. Anaphylaxis, as well serious allergic reactions, have been reported during postmarketing use with dental products containing chlorhexidine. SEE CONTRAINDICATIONS.

Precautions


General:
1. For patients having coexisting gingivitis and periodontitis, the presence or absence of gingival
inflammation following treatment with chlorhexidine gluconate oral rinse should not be used as
a major indicator of underlying periodontitis.
2. Chlorhexidine gluconate oral rinse can cause staining of oral surfaces, such as tooth surfaces,
restorations, and the dorsum of the tongue. Not all patients will experience a visually significant
increase in toothstaining. In clinical testing, 56% of chlorhexidine gluconate oral rinse users
exhibited a measurable increase in facial anterior stain, compared to 35% of control users after
six months; 15% of chlorhexidine gluconate oral rinse users developed what was judged to be
heavy stain, compared to 1% of control users after six months. Stain will be more pronounced
in patients who have heavier accumulations of unremoved plaque. Stain resulting from use of
chlorhexidine gluconate oral rinse does not adversely affect health of the gingivae or other oral
tissues. Stain can be removed from most tooth surfaces by conventional professional
prophylactic techniques. Additional time may be required to complete the prophylaxis.
Discretion should be used when prescribing to patients with anterior facial restorations with
rough surfaces or margins. If natural stain cannot be removed from these surfaces by a dental
prophylaxis, patients should be excluded from chlorhexidine gluconate oral rinse treatment if
permanent discoloration is unacceptable. Stain in these areas may be difficult to remove by
dental prophylaxis and on rare occasions may necessitate replacement of these restorations.
3. Some patients may experience an alteration in taste perception while undergoing treatment with
chlorhexidine gluconate oral rinse. Rare instances of permanent taste alteration following
chlorhexidine gluconate oral rinse use have been reported via post-marketing product
surveillance.

* Please review the disclaimer below.